GANX — Gain Therapeutics Share News
0.000.00%
Last trade - 00:00Gain Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Gain Therapeutics Files Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program At IWGGD Symposium
NASDAQ RESUMED AT 02:02 PM
Gain Therapeutics surges after presenting lab data on lead drug
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:00 PM
Brief: Gain Presents Data On Gaucher Disease Program
Brief: Gain Therapeutics Reports Full Year 2021 Financial Results
Brief: Gain Therapeutics Presents Preclinical Data On Its Structurally Targeted Allosteric Regulators In GBA1 Gaucher Disease
Brief: Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Gain Therapeutics Progresses Krabbe Disease Program
Brief: Gain Therapeutics Inc Reports Third Quarter 2021 Financial Results And Business Update
U.S. STOCKS ON THE MOVE-Ford, Genius Sports, GameStop
U.S. STOCKS ON THE MOVE-Virios, McAfee, Perrigo
U.S. STOCKS ON THE MOVE-PayPal, Tesla, Gain Therapeutics
Gain Therapeutics up as compounds show promise in Gaucher and Parkinson's Disease
Brief: Gain Therapeutics Announces Positive Topline Data In Patient-Derived IPSC Study Evaluating Star Compounds As Treatment For Gaucher And Parkinson’s Disease
Brief: Gain Therapeutics Q2 Loss Per Share $0.30
Gain Therapeutics Inc reports results for the quarter ended in June - Earnings Summary